ReviewJournal of oncology practice2016
Recent Insights and Advances in the Management of Merkel Cell Carcinoma.
Review in Journal of oncology practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Merkel cell carcinoma of the parotid gland: a rare case report and literature review.International journal of surgery case reports · 2025Article
- Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma.Future oncology (London, England) · 2025Article
- Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2023Article
- An Investigation of Structure-Activity Relationships and Cell Death Mechanisms of the Marine Alkaloids Discorhabdins in Merkel Cell Carcinoma Cells.Marine drugs · 2023Article
- Identification of natural product modulators of Merkel cell carcinoma cell growth and survival.Scientific reports · 2021Article
- Review
- Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma.BMJ case reports · 2019Article
- Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies.Dermatology and therapy · 2019Review
- [76-year-old female with a painless gluteal tumor : Preparation for the specialist examination: part 31].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Article
- Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.Targeted oncology · 2018Review
- Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.Cancer immunology, immunotherapy : CII · 2018Article
- Merkel cell carcinoma in the community setting: a case report.Radiation oncology journal · 2018Article
- Treatment of a Patient with Merkel Cell Skin Carcinoma Using Radiation Therapy - A Case Report.Open access Macedonian journal of medical sciences · 2018Article
- A rare case of Merkel cell carcinoma presenting as a giant intra-thoracic mass: A case report and review of the literature.Medicine · 2017Review
- Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy.Journal of oncology practice · 2016Article
- Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma.Journal of investigative medicine high impact case reportsArticle
- Complete remission of atypical Merkel cell carcinoma of eyelid with parotid gland and lymph node metastasis through chemotherapy.Taiwan journal of ophthalmologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare and highly aggressive neuroendocrine malignancy with a propensity for recurrence and a poor prognosis. Incidence of MCC is on the rise and is known to increase with advanced age, immunosuppression, and UV exposure. Merkel cell polyomavirus is implicated in the pathogenesis of virus-positive MCC and accounts for 80% of MCCs in the northern hemisphere and 25% in southern latitudes. In contrast, tumorigenesis of virus-negative MCC is linked to UV-induced DNA damage. Interplay between ubiquitous Merkel cell polyomavirus skin infections that commonly occur in healthy skin and other established risk factors, such as immunosuppression and UV exposure, remains poorly understood. Surgery and radiotherapy achieves excellent locoregional control; however, invariably, a significant proportion of patients develop disseminated disease that is incurable. Chemotherapy offers a high response rate for metastatic disease, but responses are short-lived and the impact on survival is not established. Recent advances in our understanding of the genetic landscape and immunobiology of MCC has led to investigation of novel treatments, including immune checkpoint inhibitors, which are likely to rapidly transform the way we manage these patients. We review epidemiologic, clinical, and histopathologic features of MCC; describe recent insights in MCC biology; and discuss novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.